Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Mukae - Phase 2a, 2022 jRCT2031210350

Ensitrelvir (XOCOVA) (n=-9) vs. placebo (n=-9)

randomized controlled trial   some concerns about risk of bias

Studied treatment

ensitrelvir 125 mg or 250 mg
loading dose of ensitrelvir on day1 (375 mg for the 125 mg group and 750 mg for the 250 mg group), followed by the maintenance dose (125 mg for the 125 mg group and 250 mg for the 250 mg group) on days 2 through 5 without dose modification

Control treatment

placebo

Patients

COVID-19 mild to moderate

A majority of the patients in the ITT population had been vaccinated (ensitrelvir 125 mg, 14 [87.5%]; ensitrelvir 250 mg, 12 [85.7%]; and placebo, 123 12 [70.6%])

Method

double blind

japan, 56 centers

Remark